Dr. Le On The Rationale For Tepotinib In Metex14-Mutant Nsclc

Dr. Le on the Rationale for Tepotinib in METex14-Mutant NSCLC

Dr. Le on the Design of the VISION Trial in METex14-Mutant NSCLC

Tepotinib in METex14 skipping alteration NSCLC

VISION: tepotinib in MET exon 14 skipping NSCLC

The importance of METex14 testing in NSCLC

Dr. Drilon on Tepotinib and Gefitinib in MET+ EGFR-Mutant NSCLC

The challenges of treating METex14 NSCLC

FDA Priority Review of Capmatinib for METex14-Mutated NSCLC

Targeted Oncology

Xiuning Le, MD, PhD, discusses goals and results of the VISION study in non-small cell lung cancer

Dr. Reckamp on Pivotal Data in METex14-Altered NSCLC

Amivantamab for NSCLC with MET Exon 14 skipping mutations

VISION trial: subset efficacy analyses of tepotinib for NSCLC

"Advancements in Treatment Sequencing: Tepotinib in METex14 NSCLC | Dr. Kripa Bajaj | CRSF 2023

CRSF - Cancer Research and Statistic Foundation

The Availability of MET Inhibitors for NSCLC

Targeted Oncology

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC

Video Journal of Biomedicine

VISION Trial Produces Positive Data in NSCLC With MET Exon 14 Mutations

Targeted Oncology

Oncologist’s opinion on the drugs for review capmatinib, tepotinib, crizotinib, and cabozantinib.

MMIT Managed Market Insights & Technology

Combining EGFR and VEGF inhibitors for NSCLC

Xiuning Le, MD, PhD, describes the ADAURA clinical study as an adjuvant treatment in NSCLC

MET Exon 14 Mutations in mNSCLC